1. Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward method was used to impute post-baseline missing ACR components.
Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward method was used to impute post-baseline missing ACR components. Subjects with insufficient data to calculate ACR20/ACR50/ACR70 responses or who withdrew from the study prior to assessment were classified as nonresponders. bDAS-ESR ≤ 3.2. cDAS-ESR < 2.6. dEULAR moderate and good responses were achieved by 34.1% and 9.1% of patients at Week 24, and 43.8% and 18.2% of patients at Week 48, respectively. ACR: American College of Rheumatology; DAS: Disease Activity Score; ESR: erythrocyte sedimentation rate; EULAR: European League Against Rheumatism; LDA: low disease activity.
William F.C. Rigby et al. J Rheumatol 2013;40:
©2013 by The Journal of Rheumatology